InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Investor Presentation and Conference Call Recording 10 May 2018 4:51PM $0.390 $0.360 fallen by 7.69%
- Investor Presentation and Conference Call 9 May 2018 4:22PM $0.400 $0.360 fallen by 10%
- Change in Substantial Holding - Christopher Collins 9 May 2018 4:04PM $0.400 $0.360 fallen by 10%
- Final Director's Interest Notice - Andrew Sneddon 4 May 2018 9:49AM $0.335 $0.360 risen by 7.46%
- Final Director's Interest Notice - Elizabeth Hopkins 4 May 2018 9:48AM $0.335 $0.360 risen by 7.46%
- Final Director's Interest Notice - Chris Collins 4 May 2018 9:47AM $0.335 $0.360 risen by 7.46%
- Final Director's Interest Notice - Michael Quinn 4 May 2018 9:45AM $0.335 $0.360 risen by 7.46%
- Initial Director's Interest Notice - Andrew Cooke 4 May 2018 9:41AM $0.335 $0.360 risen by 7.46%
- Initial Director's Interest Notice - Christopher Burns 4 May 2018 9:40AM $0.335 $0.360 risen by 7.46%
- Initial Director's Interest Notice - Warwick Tong 4 May 2018 9:38AM $0.335 $0.360 risen by 7.46%
- Initial Director's Interest Notice - Christian Behrenbruch 4 May 2018 9:34AM $0.335 $0.360 risen by 7.46%
- Amplia Acquisition Completed and New Board Appointments 4 May 2018 9:25AM $0.335 $0.360 risen by 7.46%
- Appendix 3B - Amplia Acquisition 4 May 2018 9:22AM $0.335 $0.360 risen by 7.46%
- App 4C - March 2018 Quarterly Cash Flow Report 30 Apr 2018 10:14AM $0.042 $0.360 risen by 757.14%
- Results of Meeting 26 Apr 2018 11:18AM $0.043 $0.360 risen by 737.21%
- Acquisition of Amplia Therapeutics - Questions and Answers 6 Apr 2018 8:22AM $0.067 $0.360 risen by 437.31%
- Consolidation/Split - IIL 28 Mar 2018 5:15PM $0.071 $0.360 risen by 407.04%
- Notice of General Meeting/Proxy Form 28 Mar 2018 1:19PM $0.070 $0.360 risen by 414.29%
- Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates 23 Mar 2018 8:25AM $0.031 $0.360 risen by 1,061.29%
- S&P DJ Indices Announces March Quarterly Rebalance 9 Mar 2018 8:28AM $0.029 $0.360 risen by 1,141.38%
- Appendix 4C - December 2017 Quarter 31 Jan 2018 9:23AM $0.033 $0.360 risen by 990.91%
- Half Yearly Report and Accounts - HY ending 30 Sep 2017 30 Nov 2017 1:22PM $0.026 $0.360 risen by 1,284.62%
- Appendix 4C - September 2017 Quarter Cashflows 30 Oct 2017 9:03AM $0.026 $0.360 risen by 1,284.62%
- Corporate Update 20 Oct 2017 8:23AM $0.031 $0.360 risen by 1,061.29%
- Change of Director's Interest Notice - Chris Collins 26 Sep 2017 9:54AM $0.032 $0.360 risen by 1,025%

26 - 50 of 191 results

Page 2 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.